液晶结构会影响Pluronic®凝中的药物释放
Tingting Li1, Mayra Daniela Morales-Acosta2, Diane J Burgess1
1Department of Pharmaceutical Sciences, University of Connecticut, Storrs CT-06269, USA.
International journal of pharmaceutics
|December 3, 2025
概括
普鲁罗尼克®凝通过液晶结构变化控制疏水性药物释放,而疏水性药物释放不受影响. 这项研究澄清了口腔粘膜炎疼痛管理的药物释放机制.
科学领域:
- 材料科学 材料科学 材料科学
- 制药科学 制药科学
- 药物运输 药物运输 药物运输
背景情况:
- 装有布皮瓦卡因盐 (Bup-γL) 的Pluronic®凝用于治疗口腔粘膜炎的疼痛.
- 这些Pluronic®凝的药物释放机制尚未完全理解.
- 了解释放机制对于优化基于Pluronic®的配方至关重要.
研究的目的:
- 为了研究Pluronic®凝中的药物释放机制.
- 为了探索硫酸 (SLS) 对药物释放的影响.
- 为了将液晶结构与药物释放动力学相关联.
主要方法:
- 在体外释放水友性 (BupHCl) 和水性 (Bup-γL,Bup-L) 布皮瓦卡因盐的研究.
- 使用小角度X射线散射 (SAXS) 分析Pluronic®凝结构.
- 复合剂的风病学和纳米差异扫描热量计 (纳米DSC) 分析.
主要成果:
- 与六角相相比,SLS诱导的立方相 (bcc,fcc) 中的疏水性药物释放 (Bup-γL,Bup-L) 显著较慢.
- 水友性药物释放 (BupHCl) 在SLS诱导的叶片和六角相之间没有显著差异.
- 液晶结构显著影响了疏水性药物释放,而不是疏水性药物释放.
结论:
- 液晶结构决定了Pluronic®凝中的药物释放行为,特别是对于疏水药物.
- 这些发现提供了对口腔粘膜炎疼痛控制的布皮瓦卡因盐释放机制的洞察.
- 结果为设计未来基于Pluronic®的药物输送系统以控制释放提供了有价值的指导.
相关概念视频
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
647
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
647
Polymer Classification: Crystallinity
3.7K
Unlike ionic or small covalent molecules, polymers do not form crystalline solids due to the diffusion limitations of their long-chain structures. However, polymers contain microscopic crystalline domains separated by amorphous domains.
Crystalline domains are the regions where polymer chains are aligned in an orderly manner and held together in proximity by intermolecular forces. For example, chains in the crystalline domains of polyethylene and nylon are bound together by van der Waals...
Crystalline domains are the regions where polymer chains are aligned in an orderly manner and held together in proximity by intermolecular forces. For example, chains in the crystalline domains of polyethylene and nylon are bound together by van der Waals...
3.7K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
480
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
480
Factors Influencing Drug Absorption: Pharmaceutical Parameters
382
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
382
Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.5K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.5K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
135
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
135


